Tag: shares

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia’s common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.

MERIDIAN, Idaho, Aug. 01, 2025 (GLOBE NEWSWIRE) -- PCS Edventures!, Inc. (“PCSV”), a leading provider of TK-12 Science, Technology, Engineering and Mathematics (“STEM”) education programs, today announced that it has repurchased 3,736,170 of its outstanding shares on the open market in the period from July 07, 2025, up to and including July 28, 2025.

BALA CYNWYD, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Performant Healthcare, Inc. (“Performant Healthcare” or the “Company”) (Nasdaq - PHLT) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Machinify. Under the terms of the transaction, Machinify will acquire all outstanding shares of Performant Healthcare for $7.75 per share in cash.

Transaction in Own Shares   

SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results.

Dans le cadre de la mise en œuvre de son programme de rachat d’actions, VINCI a signé le 1^er août 2025 une convention d’achat d’actions avec un prestataire de service d’investissement.

As part of the implementation of its share buyback programme, VINCI signed a share purchase agreement with an investment services provider on 1^st August 2025.